Premium
Efficacy of transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia
Author(s) -
Namiki Kazunori,
Shiozawa Hiroaki,
Tsuzuki Masahiro,
Mamiya Yoshimi,
Matsumoto Tetsuo,
Miki Makoto
Publication year - 1999
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.1999.00073.x
Subject(s) - medicine , prostate , urology , hyperplasia , international prostate symptom score , quality of life (healthcare) , lower urinary tract symptoms , ablation , urinary flow , nursing , cancer
Background: We evaluated the efficacy and safety of transurethral needle ablation (TUNA TM ) of the prostate for treatment of symptomatic benign prostatic hyperplasia (BPH) as one institute participating in a Japanese clinical trial. Methods: Thirty‐three patients with symptomatic BPH were treated with the TUNA TM procedure in our institute. The international prostate symptom score (IPSS), quality of life (QOL) score, residual urine volume (RV), prostate volume (PV) and peak urinary flow rates (Qmax) were measured and complications were assessed. Results: We followed and evaluated 30 of the 33 cases. At 12 months there were significant improvements in the IPSS (20.7 to 11.2, P < 0.0001), QOL score (4.9 to 2.1, P < 0.0001), RV (46.6 to 22.6 mL, P < 0.01), PV (37.8 to 30.0 mL 3 , P < 0.002) and Qmax (8.00 to 11.0 mL/s, P < 0.002). There were no serious complications. Conclusion: This trial shows that the TUNA TM procedure is a safe and efficacious treatment for symptomatic BPH.